LCH in Adults


During the Fall of 2020, our website will be undergoing a major redesign in look, feel and content to provide you with the best tools for finding information and resources to help you on your journey with histio. We encourage you to browse our latest educational webinars for the most recent disease information, particularly around COVID-19 concerns. Visit our COVID-19 Histio Hub for resources associated specifically with the coronavirus and histiocytosis.

Latest LCH Educational Webinar


Langerhans cell histiocytosis (LCH) in adults is a rare disorder that occurs when the body produces too many Langerhans cells (histiocytes), which are a type of white blood cell that helps fight infection. While Langerhans cells are found in normal, healthy people, there is an over-production and build-up of these cells which can lead to organ damage in adults with LCH.

Although some forms of this disease were first described over a century ago, it has only been in recent years that LCH has received more attention, especially in adults.

The name for this disease has evolved over the years, as new information has been discovered. Previously known as Hashimoto-Pritzker syndrome, Letterer-Siwe disease, Hand-Schüller-Christian disease, eosinophilic granuloma and histiocytosis X, the name  “Langerhans cell histiocytosis” was later introduced. This name was agreed upon to recognize the central role of the Langerhans cell.

To date, no large-scale studies have been done on how often LCH occurs in adults. It is estimated that it occurs in 1-2 adults per million people. It is important to remember that there are still many undiagnosed/misdiagnosed patients. The length of time from presenting symptoms to diagnosis can be years, which emphasizes the importance of finding a physician who is knowledgeable about this disease.

Information has been collected in various studies, including the 2001 International Histiocyte Society Registry on 274 adults from 13 countries. In this study, it was reported that 31% of patients had disease in a single system, 68% had more than one system involved, and 30% had pituitary involvement with diabetes insipidus. According to another registry based in Germany, it is estimated that 46% of adult patients had bone lesions, 17% skin, 7% pituitary, 4% liver/spleen, 2% brain, and 2% GI tract.

It is estimated that 63% of adults with LCH have lung-only disease, pulmonary Langerhans cell histiocytosis (PLCH), although it can also occur with other involvement, such as bone, skin or diabetes insipidus. Although the cause is unknown, it is believed that 90-95% of adults with this disease are past or current smokers, suggesting that smoking is related. It has also been reported that children with LCH in organs other than the lungs who acquire the habit of cigarette smoking in adulthood may develop PLCH, sometimes years after the initial diagnosis.

There are no known environmental risk factors associated with LCH, with the exception of cigarette smoking in lung disease.

In recent years, there has been increasing evidence to support the idea that LCH is a “neoplasm,” which means that LCH tumors contains cells with mistakes in their genes, also called “gene mutations,” that cause the cells to make copies of themselves inappropriately. When cells are making too many copies of themselves, this causes LCH lesions to grow. There is a specific gene called BRAF that has a mutation in about one half of LCH tumors. Recent research has identified other genes with mutations in LCH lesions but this requires further research. As of 2020, according to most experts Langerhans cell Histiocytosis (LCH) is currently classified as a rare cancer, however this doesn't necessarily mean that all of the worrisome implications that come along with the term “cancer” are true of LCH for every patient; LCH and other histiocytic disorders have a wide spectrum of presentations.

LCH can be systemic, and most often an oncologist/hematologist takes the main role in treating patients. However, since LCH can affect so many areas of the body, sometimes a team approach may be appropriate, and the oncologist may enlist the help of various types of specialists such as surgeons, pulmonologists (lung), dermatologists (skin), dentists or endocrinologists (diabetes/hormones) to give their input.

Most patients will survive the disease. Some will remain symptom free, while others may develop life-long problems. In some cases, especially those that are not treated and/or followed closely, the disease may become life threatening. Read more about Permanent Consequences and Late Effects of LCH.

The patient's chances for survival and maintaining good quality of life depend on the individual case, but research has suggested that the course is less favorable for elderly patients, those with multiple locations of disease and those who may have risk-organ (lungs, liver, spleen, bone marrow) involvement. Limited involvement can also become serious, depending on the particular sites involved, how quickly the disease continues to progress and the patient's response to treatment.

Overall, physicians will be able to discuss each patient's likelihood of responding and doing well, but it is often difficult for doctors to make definite predictions since LCH has clearly shown itself to be an unpredictable disease.

>> Resource for PLCH Patients
>> Read Frequently Asked Questions about LCH in Adults

>> View printable LCH Fact Sheet

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
US & Canada Toll-Free: 1-800-548-2758 
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us 

¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: Nosotros podremos responderle tan pronto nos sea possible. Gracias!